An activated set point of T-cell and monocyte inflammatory networks in recent-onset schizophrenia patients involves both pro- and anti-inflammatory forces

Drexhage, Roosmarijn C.; Hoogenboezem, Thomas A.; Cohen, Dan; Versnel, Marjan A.; Nolen, Willem; van Beveren, Nico J. M.; Drexhage, Hemmo A.

Published in:
International Journal of Neuropsychopharmacology

DOI:
10.1017/S1461145710001653

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2011

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
An activated set point of T-cell and monocyte inflammatory networks in recent-onset schizophrenia patients involves both pro- and anti-inflammatory forces

Roosmarijn C. Drexhage1, Thomas A. Hoogenboezem1, Dan Cohen2,3, Marjan A. Versnel1, Willem A. Nolen4, Nico J. M. van Beveren5 and Hemmo A. Drexhage1

1 Department of Immunology, Erasmus MC, Rotterdam, The Netherlands
2 GZ-NHN, Heerhugowaard, The Netherlands
3 Department of Epidemiology, University Medical Center, Groningen, The Netherlands
4 Department of Psychiatry, University Medical Center, Groningen, The Netherlands
5 Department of Psychiatry, Erasmus MC, Rotterdam, The Netherlands

Abstract

We recently described a pro-inflammatory gene expression signature in the monocytes of 60% of patients with recent-onset schizophrenia (SCZ). Here we investigated whether the T-cell system is also in a pro-inflammatory state. A detailed fluorescence-activated cell sorting (FACS) analysis, e.g. of CD3+CD25+ T cells, IFN-γ+, IL-4+, IL-17A+ (CD4+) lymphocytes and CD4+CD25hiFoxP3+ regulatory T cells, was performed on peripheral blood of 26 patients with recent-onset SCZ (in 19 of whom the inflammatory gene expression signature of the monocyte had been determined) and in age-/gender-matched healthy controls. Various relevant T-cell cytokines, e.g. sCD25, IFN-γ, IL-17A and IL-4, were measured in serum by a multiplex assay. We detected: (a) not only higher percentages of pro-inflammatory-prone monocytes, activated CD3+CD25+ T cells and pro-inflammatory Th17 cells in patients, but also higher percentages of anti-inflammatory CD4+CD25hiFoxP3+ regulatory T cells and IL-4+ lymphocytes; (b) that this activated T-cell set point was reflected in significantly raised serum levels of sCD25; (c) that the up-regulation of IL-4+ containing lymphocytes was predominantly found in patients characterized by a monocyte pro-inflammatory set point; and (d) that regulatory T-cell and Th17-cell numbers were higher in patients irrespective of the pro-inflammatory state of the monocytes. Our data do not support the concept that the T-cell system is in a simple pro-inflammatory state in recent-onset SCZ, but do show that the monocyte and T-cell networks are activated and involve both pro- and anti-inflammatory forces. This suggests control within an activated inflammatory system.

Received 10 September 2010; Reviewed 10 November 2010; Revised 22 November 2010; Accepted 17 December 2010; First published online 24 January 2011

Key words: Activated inflammatory response system, cytokines, regulatory T cells, schizophrenia, Th17.

Introduction

There is accumulating evidence that activation of the inflammatory response system plays an important role in the pathogenesis of schizophrenia (SCZ). In support of this view we recently described an inflammatory gene expression signature, i.e. a coherent aberrant expression of a set of 34 pro-inflammatory genes, in the circulating monocytes of around 60% of patients with recent-onset SCZ (Drexhage et al. 2010b).

Apart from cells of the monocyte lineage, T cells are important contributors to the inflammatory response, but literature on T-cell numbers and cytokines is scarce and conjectural in SCZ. Although it has been shown (Denicoff et al. 1987) that infusion with IL-2, the well-known growth factor for T cells, is capable of inducing psychosis-related symptoms in psychiatrically
healthy individuals, there are at present inconclusive results on the levels of IL-2 or its soluble receptor (sIL-2R, synonymous to sCD25) in the circulation of SCZ patients (Drexhage et al. 2010a). The same holds true for the blood levels of IFN-γ and IL-4, the hallmark cytokines of the CD4⁺Th1 and Th2 cell subsets, respectively; higher (Kaminska et al. 2001; O'Brien et al. 2008), lower (Kim et al. 2009) or unaltered (Kim et al. 2004) levels of these cytokines and T-cell subsets have been described in SCZ patients.

In recent years a new pro-inflammatory T-cell cytokine IL-17, has been discovered predominantly produced by so-called CD4⁺TH17 cells (Bettelli et al. 2008). TH17 cells protect the host against bacteria and fungi by activating macrophages via the production of IL-17 (and also IL-21 and IL-22). In contrast, they also play a role in the pathogenesis of autoimmune diseases such as psoriasis and rheumatoid arthritis (Bettelli et al. 2008). Functions of TH17 cells are thus similar to those of TH1 cells.

The inflammation-inducing effects of TH17, TH1 cells and of monocytes/macrophages are controlled by a special class of T cells, i.e. the regulatory CD4⁺CD25⁺FoxP3⁺ T cells (Hori et al. 2003; Wing & Sakaguchi, 2010). The main function of these inborn, thymus-derived regulatory T cells is to temper the inflammatory response thereby maintaining homeostasis and tolerance to self-antigens. The cytokines involved in this anti-inflammatory action are thought to be IL-10 and TGF-β. Patients lacking these regulatory T cells due to a genetic mutation in the gene coding for FoxP3 suffer from a severe and rapidly lethal autoimmune syndrome (immune dysregulation, polyendocrinopathy, enteropathy X-linked syndrome) (Wildin et al. 2002).

The aim of this study was to evaluate T-cell-related inflammatory networks in SCZ following the hypothesis that not only the monocyte system, but also the inflammatory networks in SCZ following the hypoth-

### Methods

#### SCZ patients

Twenty-six acutely psychotic in-patients with SCZ diagnosed according to DSM-IV criteria were recruited at the department of Psychiatry of the Erasmus Medical Centre in Rotterdam. SCZ was diagnosed according to the DSM-IV criteria after a Comprehensive Assessment of Symptoms and History (CASH) interview (Andreasen et al. 1992) and by consensus between two senior psychiatrists who were blinded to the results based on all clinical available evidence. In patients with symptoms for <6 months, a final diagnosis was made after 6 months to comply with the DSM-IV criterion. All patients were acutely psychotic on admission. The patients level of functioning on admission and at discharge was determined by the GAF score on the fifth axis of DSM-IV.

The SCZ patients were virtually all (except one) recent-onset cases and had a median duration of illness of only 0.3 yr (median, range 0–3 yr). Absence of severe medical illness (including infections and allergies) was established by medical history assessment, physical examination and routine laboratory testing (Hb, Ht, leukocyte count, blood smear, kidney/liver function) on admission. Almost all patients were receiving antipsychotic medication at the time of blood draw; however, with a low lifetime cumulative haloperidol equivalent (median 42 mg Hal equiv.) (Cahn et al. 2002) none of the patients were drug naive.

The demographics of the patients are summarized in Table 1.

#### Healthy controls (HC)

Age- and gender-matched HC (Table 1) were recruited from laboratory staff, medical staff and medical students. The inclusion criteria for HC were an absence of any psychiatric or autoimmune disorder in themselves and in first-degree relatives. HC had to be in self-proclaimed good health and free of any obvious medical illness for at least 2 wk prior to blood draw, including acute infections and allergic reactions.
The Medical Ethical Review Committee of the Erasmus MC Rotterdam approved the study. Written informed consent was obtained from all participants after a complete description of the study had been given.

**Laboratory methods**

**Blood collection and preparation**

Blood (drawn in the morning hours) was collected in clotting tubes for serum preparation (stored at $-80\,^\circ C$) and in sodium-heparin tubes for immune cell preparation, on average 20 ml blood was collected from each patient. From the heparinized blood, peripheral blood mononuclear cell (PBMC) suspensions were prepared by low-density gradient centrifugation, as described in detail elsewhere (Knijff et al. 2006), within 8 h to avoid activation of the monocytes (erythrophagy). PBMCs were frozen in 10% DMSO and stored in liquid nitrogen. This enabled us to test patient and control immune cells in the same series of experiments performed later.

**Flow cytometric analyses**

FACS analysis was used to measure intracellular cytokine content in PBMC of patients and age- and gender-matched HC. As hallmark intracellular cytokines we used: IFN-$\gamma$, IL-4 and IL-17A. To enable the enumeration of regulatory T cells we intracellularly stained for FoxP3. Membrane staining was done for CD3, CD4, CD25 and CD45RO. This enabled us to assign cytokine staining to the enigmatic Th1, Th2 and Th17 cells in either the total population of CD4$^+$ cells or the memory population. It also enabled us to enumerate the enigmatic regulatory CD4$^+$CD25$^{high}$FoxP3$^+$ T-cell population.

For the analysis PBMCs were suspended in complete culture medium. Cell suspensions were then stimulated with PMA (Sigma Aldrich, USA), ionomycin (Sigma Aldrich) in the presence of Golgistop (Becton Dickinson, USA) for 4 h in 37 $^\circ C$ under a 5% CO$_2$ environment for T effector cells, regulatory T cells were not stimulated.

Cells were harvested and stained extracellularly with anti-CD4 (PerCP-Cy5.5; Becton Dickinson) and anti-CD45RO FITC (Dako, Denmark). For determination of regulatory T cells, non-stimulated PBMC samples were stained with anti-CD3 (PerCP; BD Biosciences, USA), anti-CD4 (APC; BD Biosciences) and anti-CD25 (FITC; BD Biosciences) according to standard protocol.

Following extracellular staining, the cells were fixed and permeabilized according to the manufacturer’s instructions (eBioscience, USA) and then stained for FoxP3 (PE; Becton Dickinson), IL-4 (PE; Becton Dickinson), IFN-$\gamma$ (APC; Becton Dickinson), IL-17A (PE; eBioscience). Isotype antibody controls were used to confirm antibody specificity for CD25. Stained cells were analysed by four-colour flow cytometry (FACScalibur, BD Biosciences) as described previously and analysed using FlowJo (Tree Star Inc., USA) research software. Supplementary Fig. 1 (available online) gives the dot plots of the stainings and definition of cell populations.

**mRNA gene expression in monocytes**

The definition and determination of mRNA gene expression fingerprints in monocytes has been previously described in detail (Drexhage et al. 2010b).

**Serum cytokine determinations**

Serum cytokines (IFN-$\gamma$, IL-17, IL-10, IL-4, TNF-$\alpha$, CCL2, IL-5, IL-1$\beta$, PTX3) were measured using the Cytometric Bead Array kits (BenderMedSystems, USA) according to the manufacturer’s protocol. Bead flow cytometry allows the simultaneous quantification of various proteins in the same test (http://www.bendermedsystems.com/bm_files/47/BM_Factsheet_3_A4_SCREEN.pdf). Twenty-five $\mu l$ of serum per test were used. Samples were analysed in a FACSCanto flow cytometer (BD Biosciences) using the

---

**Table 1. Characteristics of patients with schizophrenia and healthy controls**

<table>
<thead>
<tr>
<th></th>
<th>Schizophrenia</th>
<th>Healthy controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group size</td>
<td>26</td>
<td>26</td>
</tr>
<tr>
<td>Age (yr)$^*$</td>
<td>24 (17–39)</td>
<td>25 (21–39)</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>23 (88%)</td>
<td>23 (88%)</td>
</tr>
<tr>
<td>Female</td>
<td>3 (12%)</td>
<td>3 (12%)</td>
</tr>
<tr>
<td>Smoking</td>
<td></td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Typical antipsychotics</td>
<td>13</td>
<td></td>
</tr>
<tr>
<td>Atypical antipsychotics</td>
<td>12</td>
<td></td>
</tr>
</tbody>
</table>

GAF, Global assessment of functioning. GAF range from 0 to 100, higher scores indicate better functioning.

$^*$ Median with range.
FlowCytomix Pro 2.3 Software (BenderMedSystems). Results are expressed as picograms per millilitre.

For TGF-β (Diaclone, France) and sIL-2r (R & D Systems, USA) commercially available ELISAs were used according to the manufacturer’s protocol.

**Statistics**

Statistical analysis was performed using the SPSS 15.0 package for Windows (SPSS Inc., USA). Data were tested for normal distribution using the Kolmogorov–Smirnov test. Parametric tests were used when the data had a normal distribution. When normal distribution was not reached, data were log-transformed. In the text, tables and figures the original data have been used. Levels of significance were set at \( p = 0.05 \) (two-tailed). The specific tests used are mentioned in the tables and figure legends.

**Results**

**Percentages of monocytes and lymphocytes**

FACS analysis of the samples showed that the percentage of monocytes was higher in SCZ samples compared to those of the gender- and age-matched HC (SCZ: 24.33 ± 7.91; HC: 20.64 ± 4.52; \( p = 0.049 \), Mann–Whitney test). Although the percentage of lymphocytes was smaller in the SCZ samples compared to the HC, values did not reach statistical significance (SCZ: 70.97 ± 7.90; HC: 75.08 ± 5.02; \( p = 0.077 \), Mann–Whitney test). Blood leukocyte counts were within the normal range on admission for all patients (routine clinical determination, mean 6.4 ± 1.5 × 10^9/l, reference range for our centre: 3.5–10.0 × 10^9/l).

**IFN-γ, IL-4- and IL-17A-containing lymphocytes**

Using FACS we first analysed the capability of the total lymphocyte fraction to produce IFN-γ, IL-4 and IL-17A. After stimulation with PMA and ionomycin for 4 h (a procedure to re-activate lymphocytes), the percentages of IFN-γ- and IL-17A-containing lymphocytes were not different between SCZ samples and HC samples: IFN-γ (SCZ: 24.47 ± 7.60; HC: 27.63 ± 9.45; \( p = 0.199 \)) IL-17A (SCZ: 0.39 ± 0.29; HC: 0.27 ± 0.12; \( p = 0.137 \)). However, lymphocytes capable of producing IL-4 were more numerous in SCZ patients compared to lymphocytes of HC (Fig. 1a). Differences could not be detected with regard to the mean fluorescence intensity (MFI), which reflects the actual content of the cytokine per lymphocyte.

**CD3^+CD25^+ cells**

Activation of T cells is classically determined by CD25 (IL-2r) expression, illustrating the higher capability of T cells to react to the growth factor IL-2. Percentages of CD3^+CD25^+ T cells were higher in SCZ patients compared to HC (Fig. 1c). Moreover, serum levels of the shed receptor, sCD25 (=sIL-2r), were also higher in SCZ patients and correlated positively with CD3^+CD25^+ T cells (\( r = 0.394, p = 0.007 \)) and IL-4-containing lymphocytes (\( r = 0.462, p = 0.001 \)).

**Classical Th1 (CD4^+IFN-γ^+), Th2 (CD4^+IL-4^+), Th17 (CD4^+IL-17A^+) and regulatory CD4^+CD25\text{high}FoxP3^+ T cells**

We subsequently studied the percentages of classical Th1 cells (CD4^+ T cells capable of producing IFN-γ), classical Th2 cells (CD4^+ T cells capable of producing IL-4) or classical Th17 cells (CD4^+ T cells capable of producing IL-17A).

The percentage of classical Th1 cells was not different in SCZ patients (SCZ: 7.55 ± 4.19; HC: 7.30 ± 3.50; \( p = 0.905 \)), while that of classical Th2 cells showed a trend to be higher in line with the finding that IL-4-producing lymphocytes were higher (Fig. 1b).

Statistically, higher percentages of classical Th17 cells were found in the circulation of SCZ patients compared to that of HC (Fig. 1d). Virtually all these Th17 cells were of memory type, i.e. they were CD45RO^+.

Figure 1e also shows that CD4^+CD25\text{high}FoxP3^+ T-cell (regulatory T cells) percentages were higher in SCZ patients compared to HC (Fig. 1e). There was a strong positive correlation between the percentage of regulatory T cells and the serum levels of sIL-2R in the patients (\( r = 0.447, p = 0.002 \)).

**Correlations between the different T-cell subsets (Table 2)**

The percentages of CD3^+CD25^+ cells correlated significantly with the percentages of regulatory T cells, classical Th1 cells and Th17 cells, but not with Th2 cells. Percentages of Th17 cells correlated with those of Th1 cells, but not with Th2 cells. The percentages of regulatory T cells did not correlate with those of Th17 cells. There was also no correlation for regulatory T cells and Th1 or Th2 cells. Although the correlation coefficient was negative for the correlation between Th1 and Th2 cells (as could be expected from the reciprocal character of the subsets), values did not reach statistical significance.

---

License: Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Downloaded from https://academic.oup.com/ijnp/article-abstract/14/6/746/916243 by University Library user on 13 June 2018
Levels of IFN-γ, IL-17, IL-10, IL-6, IL-4 and TNF-α were lower than the detection limit in the serum of patients and controls (Table 3).

Levels of CCL2, IL-5, IL-1β and PTX3 were detectable, but levels were not different in the serum of SCZ patients compared to those of HC. Levels of the Th17-related cytokine IL-22 and of the regulatory T-cell-related cytokine TGF-β were higher in the serum of SCZ patients;
however, levels did not reach statistical significance (Table 3).

We were unable to find correlations between the cytokines listed in this section and the percentages of the various T-cell subsets.

**Relation of T-cell inflammatory parameters to clinical variables**

We were unable to find any correlation between the T-cell variables reported here and antipsychotic drugs, smoking, positive symptoms, negative symptoms or GAF score on admission.

A positive correlation was found between the level of functioning of SCZ patients at discharge and their regulatory T-cell percentages on admission (Fig. 2). Patients with regulatory T-cell percentages >3.25% (n=16) on admission all had a GAF score of ≥50 at discharge, whereas all patients (n=7) with regulatory T-cell percentages <3.25% had a GAF score of ≤49 at discharge (GAF score at discharge for three patients was not available). This led to a positive correlation between regulatory T-cell percentage on admission and GAF score at discharge (r=0.442, p=0.035, with Bonferroni correction for six tests statistical significance was not reached).

**Relation of T-cell inflammatory parameters to the pro-inflammatory state of patient monocytes**

Samples of 19 of the monocyte pro-inflammatory signature-tested patients could also be used in the present study and in 11/19 of these patients the signature was present compared to 3/23 of the HC [see legend of Supplementary Fig. 2 (online) for definition of a positive signature].

The higher percentages of IL-4-containing lymphocytes and of classical Th2 cells found in our SCZ patients were largely confined to SCZ patients with a positive monocyte pro-inflammatory signature (Fig. 1a, b, Supplementary Fig. 2).

The higher percentages of Th17 cells, regulatory T cells and CD3$^+$CD25$^+$ cells were found in both monocyte signature-positive and signature-negative SCZ patients. In the signature-negative patients significantly higher percentages of regulatory T cells and CD3$^+$CD25$^+$ cells were found (Fig. 1c–e).

**Discussion**

This study shows a strongly activated set point of the T-cell and monocyte inflammatory network in patients with recent-onset SCZ. On the one hand an activation of pro-inflammatory forces was found, i.e. higher percentages of circulating monocytes with a pro-inflammatory gene expression signature, activated (CD3$^+$CD25$^+$) T cells and pro-inflammatory Th17 cells, on the other hand there was also an activation of anti-inflammatory forces, i.e. increases in CD4$^+$CD25$^{high}$FoxP3$^+$ T cells and IL-4-containing lymphocytes.

The up-regulation of IL-4-containing lymphocytes and of classical Th2 cells, i.e. the CD4$^+$ population of IL-4-containing lymphocytes, was predominantly found in SCZ patients characterized by a monocyte...
pro-inflammatory gene expression set point. This constellation of the co-occurrence of pro-inflammatory-prone monocytes with higher percentages of IL-4-containing lymphocytes is counterintuitive, since IL-4 dampens the inflammatory state of monocytes and macrophages, turning the cells in so-called M2 cells (Mantovani et al. 2004). We interpret our data by hypothesizing that the higher percentage of IL-4-containing lymphocytes in these monocyte gene expression signature-positive patients serves as a control mechanism to counteract monocyte susceptibility for inflammation by keeping an actual higher production of inflammatory monocyte cytokines under control. This interpretation might then explain the normal serum levels of the pro-inflammatory monocyte/macrophage cytokines CCL2, IL-1β and PTX3 we found in our patients. On the other hand, preliminary data of our group (to be published) in a cohort of older (on average 40 yr) patients with chronic naturally treated SCZ showed a much lower inflammatory monocyte gene expression than reported here for acute SCZ, while serum levels of inflammatory cytokines were clearly raised in the group of older patients, but – apart from disease – also linked to obesity and serum lipid levels. This indicates a clear and incongruent role for disease duration, treatment, activity and/or diet/obesity in the inflammatory profiles of circulating cells and cytokine levels. This indicates further studies for biomarker development being required to control for these variables, unfortunately in this study we were had no information on metabolic parameters of patients and controls and were therefore unable to adjust for this.

Table 3. Cytokine levels in serum

<table>
<thead>
<tr>
<th></th>
<th>Schizophrenia</th>
<th>Healthy controls</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monocyte activation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CCL2</td>
<td>33.39 (12.46–60.30)</td>
<td>25.74 (14.10–60.90)</td>
<td>0.495</td>
</tr>
<tr>
<td>IL-1β</td>
<td>0.02 (0–0.55)</td>
<td>0.05 (0–2.55)</td>
<td>0.447</td>
</tr>
<tr>
<td>PTX3</td>
<td>66.50 (7.36–381.49)</td>
<td>73.07 (13.90–368.80)</td>
<td>0.493</td>
</tr>
<tr>
<td>IL-6</td>
<td>n.d.</td>
<td>n.d.</td>
<td></td>
</tr>
<tr>
<td>TNFα</td>
<td>n.d.</td>
<td>n.d.</td>
<td></td>
</tr>
<tr>
<td>T-cell proliferation activity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>sIL-2R</td>
<td>1960 ± 593</td>
<td>1496 ± 473</td>
<td>0.009</td>
</tr>
<tr>
<td>IFN-γ</td>
<td>n.d.</td>
<td>n.d.</td>
<td></td>
</tr>
<tr>
<td>Th2</td>
<td>0.05 (0–0.41)</td>
<td>0.01 (0–2.69)</td>
<td>0.281</td>
</tr>
<tr>
<td>IL-4</td>
<td>n.d.</td>
<td>n.d.</td>
<td></td>
</tr>
<tr>
<td>Th17</td>
<td>47.43 (41.17–94.38)</td>
<td>45.34 (41.17–59.98)</td>
<td>0.265</td>
</tr>
<tr>
<td>IL-22</td>
<td>n.d.</td>
<td>n.d.</td>
<td></td>
</tr>
<tr>
<td>Th17</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL-17a</td>
<td>13 872 (7602–68 981)</td>
<td>12 655 (4761–23 198)</td>
<td>0.204</td>
</tr>
<tr>
<td>TGF-β</td>
<td>n.d.</td>
<td>n.d.</td>
<td></td>
</tr>
<tr>
<td>Regulatory T cells</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>sIL-2R</td>
<td>n.d.</td>
<td>n.d.</td>
<td></td>
</tr>
</tbody>
</table>

n.d., Not detected.

Levels of cytokines are expressed as median with range. All values are in picograms per millilitre. Normal distribution was not obtained after log-transformation. The p values were calculated by Mann–Whitney tests. sIL-2R had a normal distribution and the level is expressed as mean ± standard deviation in IU/ml. The p value was calculated by ANOVA with age and gender in the model.

![Fig. 2. Relation of regulatory T cell percentage on admission and GAF score at discharge. GAF, Global assessment of functioning; % Tregs, percentage of CD4^+CD25^{high}FoxP3^{+} cells on admission; p values were tested by linear regression on log-transformed values (p=0.012, d.f.=21).](https://academic.oup.com/ijnp/article-abstract/14/6/746/916243/download)
cells also correlated with increased numbers of CD3+CD25+ T cells and higher levels of serum sCD25. Although we interpret these CD25 data as reflecting a higher tendency for T-cell proliferation, which might then underlie the higher percentages of Th17 and regulatory T cells, there are data in the literature which show that T-cell proliferation is in fact reduced in acute forms of SCZ when T cells were stimulated with anti-CD3 (Craddock et al. 2007). That study also found a normal expression of CD25 on CD4+ T cells in SCZ patients. Further studies are needed to clarify this issue.

There is strong evidence that Th17 cells are inflammation-promoting cells in chronic inflammatory conditions such as rheumatoid arthritis, asthma, psoriasis and multiple sclerosis and the number of Th17 cells as well as the levels of the Th17-derived cytokines IL-17, IL-21 and IL-22 are higher in affected tissues (Crome et al. 2010). Although SCZ patients do have molecular alterations in their brain vasculature (Harris et al. 2008), it is unknown whether Th17 cells or the Th17 cytokines pass the blood–brain barrier to exert an effect. In a mouse model of multiple sclerosis Th17 cells do migrate into the brain (Reboldi et al. 2009). Studies on post-mortem brains of SCZ patients and animal models of SCZ-like disease could prove instrumental in solving this question of Th17 influence on behaviour.

There is ample evidence that regulatory T cells are capable of dampening the effect of Th17 cells (Crome et al. 2010), Th1 cells (Wing & Sakaguchi, 2010) and pro-inflammatory monocytes (Tiemessen et al. 2007) in immune reactions. It is therefore tempting to hypothesize that the increase in anti-inflammatory regulatory T cells is meant (like that proposed for the IL-4-containing lymphocytes) to keep under control the pro-inflammatory immune forces in SCZ patients.

Another point of interest with regard to both the rise in Th17 cells and regulatory T cells is that the development of regulatory T cells has been reported to be tightly linked to that of Th17 cells. Both cell lineages share common developmental pathways (Bettini & Vignali, 2009; Crome et al. 2010). Also Foxp3-lineage-committed regulatory T cells were directly converted into IL-17-expressing cells by CpG treatment and interestingly IDO acts as a pivotal molecular switch in this process. Only in the absence of IDO does this conversion occur, whereas it was blocked when IDO was active (Baban et al. 2009). Although IDO activation and abnormal tryptophan breakdown is thought to play a role in SCZ, we were unable to find in the present study a correlation between percentages of regulatory T cells and those of Th17 cells.

With regard to clinical characteristics we found that a high regulatory T-cell percentage on admission correlated with a better clinical outcome (GAF score) at discharge. Interestingly, in this respect, is that IL-10, one of the key cytokines produced by regulatory T cells, has direct effects on brain function and is able to dampen down sickness behaviour (Richwine et al. 2009). However, effects of regulatory T cells could also be mediated by direct suppression of the pro-inflammatory immune forces in the brain, e.g. those exerted by pro-inflammatory microglia.

However, and with regard to this clinical effect, a limitation of our study is that it was not designed to investigate parameters of prediction and p values did not reach significance with Bonferroni correction. Suffice to say that a study on the predictive value of regulatory T cells for outcome in psychosis in a larger group of patients is now imperative.

Our study also has other limitations. We only used peripheral blood samples and we were not able to investigate the cerebrospinal fluid (CSF). Pathological abnormalities of the brain are probably directly reflected in the CSF, and indeed in SCZ there are reports on cell aberrations in CSF. A recent paper investigated T-cell subsets in CSF and peripheral blood of patients with a major psychiatric disorder and found an overlapping low-grade inflammation in CSF as well as in peripheral blood (Maxeiner et al. 2008). Unfortunately, we were unable to obtain CSF samples from our patients.

Furthermore, our study has a small sample size and outcomes should be replicated on a larger and independent sample size. The study subjects were the same in which the monocyte signature was determined, and it could be that this sample of SCZ patients has an extreme activation of the immune system. However, we have found a similar strong inflammatory monocyte signature in patients with mania (Drexhage et al. 2010b; Padmos et al. 2008) and in postpartum psychosis (V. Bergink, unpublished observations). In the latter conditions the T-cell system was not activated (V. Bergink, unpublished observations).

Our study is naturalistic and all patients (except one) were on very recently started antipsychotic medication. As antipsychotic medication exerts anti-inflammatory effects (Drzyzga et al. 2006; Pollmacher et al. 2000; Rybakowski, 2000), this effect on outcome cannot be ruled out (Drexhage et al. 2010b; Padmos et al. 2008). Moreover, there were more male participants than female participants in this study. Although HC were age- and gender-matched, we cannot completely rule out a general effect of gender on the activation state of monocytes and/or T cells. Moreover,
we cannot rule out a general effect of smoking in this study sample because there was a difference in the smoking status of the patients (69%) vs. our HC (35%). However, we did not find a correlation for smoking with one of the other immune parameters.

A further limitation is that our FACS data represent percentages, not the number, of cells within the lymphocyte population. We were unable to give absolute cell numbers, since we had not performed a leukocyte count in the same blood sample as used for FACS, although leukocyte counts routinely performed in the patients at the same time did not show abnormalities.

Taken together, our data do not support the concept that the T-cell system is in a simple pro-inflammatory state (our hypothesis), but do show that the monocyte and T-cell networks are activated in recent-onset SCZ and involve both pro- and anti-inflammatory forces.

The question remains as to when and why these activated set points are installed and what the consequences are for the pathology of SCZ. Here the animal models of the disease might become important tools for further study. In rodents chronic immune activation in the peri-natal period by reagents mimicking infections with commensal bacteria and viruses (such as LPS and GpC) do lead to altered set points of the inflammatory system which cause abnormalities in brain development and consequent psychosis-related behaviour (Makinodan et al. 2008; O’Mahony et al. 2009). Further studies in these animal models into aberrant set points of their macrophage/T-cell system are indicated.

Note

Supplementary material accompanies this paper on the Journal’s website (http://journals.cambridge.org/pnp).

Acknowledgements

This study was funded by KP7-HEALTH-2007-B. Acronym: Moodinflame – Grant Agreement no. 222963: ‘Early diagnosis, treatment and prevention of mood disorders targeting the activated inflammatory response system’. We thank Harm de Wit and Annemarie Wijkhujs for their excellent technical assistance, Caspar Looman for statistical advice and Sandra de Bruin for help with designing the figures.

Statement of Interest

W. A. Nolen has received grants from The Netherlands Organisation for Health Research and Development, the European Union, the Stanley Medical Research Institute, AstraZeneca, Eli Lilly, GlaxoSmithKline and Wyeth; has received honoraria/speakers’ fees from AstraZeneca, Eli Lilly, Pfizer, Servier and Wyeth; and has served on advisory boards for AstraZeneca, Cyberonics, Pfizer and Servier. D. Cohen has received grants from Eli Lilly and Janssen-Cilag; has received honoraria/speakers’ fees from AstraZeneca, Bristol–Myers Squibb and Eli Lilly; and has served on advisory boards of Bristol–Myers Squibb and Eli Lilly.

References


Drzygala I, Obuchowicz E, Marcinowska A, Herman ZS (2006). Cytokines in schizophrenia and the effects of...
antipsychotic drugs. *Brain, Behaviour, and Immunity* 20, 532–545.


